Evidence map›Paper›PMID 33872788›Full record

ArticleThe Journal of molecular diagnostics : JMD2021

Commercially Available Blocking Oligonucleotides Effectively Suppress Unwanted Hemolysis-Related miRNAs in a Large Whole-Blood RNA Cohort.

Jenna LaBelle, Mark Bowser, Alison Brown, Leanna Farnam, Alvin Kho, Jiang Li, Michael McGeachie, Robert Chase, Shannon Piehl, Kevin Allen and 5 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Study of MicroRNAs Expression in Food Allergy.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  6. Article
  7. Article
  8. miRNA-486-5p: signaling targets and role in non-malignant disease.Cellular and molecular life sciences : CMLS · 2022
    Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Jenna LaBelleMass General Brigham Personalized Medicine, Partners Healthcare, Cambridge, Massachusetts.
Mark BowserMass General Brigham Personalized Medicine, Partners Healthcare, Cambridge, Massachusetts.
Alison BrownMass General Brigham Personalized Medicine, Partners Healthcare, Cambridge, Massachusetts.
Leanna FarnamSchool of Health Sciences, Lasell University, Auburndale, Massachusetts.
Alvin KhoChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Jiang LiChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Michael McGeachieChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Robert ChaseChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Shannon PiehlPerkinElmer Inc., Waltham, Massachusetts.
Kevin AllenPerkinElmer Inc., Waltham, Massachusetts.
Brian D HobbsChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Scott T WeissMass General Brigham Personalized Medicine, Partners Healthcare, Cambridge, Massachusetts; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Craig HershChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Kelan TantisiraChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Sami S AmrMass General Brigham Personalized Medicine, Partners Healthcare, Cambridge, Massachusetts; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: samr@bwh.harvard.edu.
Brigham and Women's Hospital · USMass General Brigham · USPerkinElmer (United States) · USLasell College · US

Funding

Genetic Epidemiology of COPDU01HL089897 · NHLBI · NATIONAL JEWISH HEALTH · PI CRAPO, JAMES D · 2007 to 2021
$56.9M
Genetic Epidemiology of COPDU01HL089856 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K · 2007 to 2021
$20.7M
Asthma Exacerbations and MicroRNA prediction: Treatment Response in an Underserved Ethnicity (AEM-TRUE)R01HL139634 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MCGEACHIE, MICHAEL JOHN · 2018 to 2022
$4.3M
SYSTEMS GENOMICS OF THE ASTHMA-COPD OVERLAP SYNDROMER01HL130512 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HERSH, CRAIG P · 2016 to 2019
$3.5M
INTEGRATIVE GENOMICS OF CLINICAL SUBTYPES IN COPDGENER01HL125583 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HERSH, CRAIG P · 2015 to 2018
$3.5M
MICRORNAS IN CIRCULATION: ONTOLOGIES OF ASTHMA SEVERITY AND TREATMENT (MICROCOAST)R01HL127332 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G · 2015 to 2018
$3.4M
DISEASE AND HEALTH: ASTHMA RESILIENCE THROUGH MICRORNA ATTRIBUTES (DHARMA)R01HL129935 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G · 2015 to 2017
$1.4M
Multi-omic Subtyping of Chronic Obstructive Pulmonary DiseaseK08HL136928 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HOBBS, BRIAN DANIEL · 2017 to 2021
$864k
NHLBI NIH HHS K08 HL136928NHLBI NIH HHS R01 HL125583NHLBI NIH HHS R01 HL127332NHLBI NIH HHS R01 HL129935NHLBI NIH HHS R01 HL130512NHLBI NIH HHS R01 HL139634NHLBI NIH HHS U01 HL089856NHLBI NIH HHS U01 HL089897
6 · The paper itself

Abstract

When sequencing small RNA libraries derived from whole blood, the most abundant microRNAs (miRs) detected are often miR-486-5p, miR-451a, and miR-92a-3p. These highly expressed erythropoietic miRs are released into the sample from red blood cell hemolysis. Next-generation sequencing of these unwanted miRs leads to a waste in sequencing cost and diminished detection of lowly expressed miRNAs, including many potential miRNA biomarkers. Previous work has developed a method to reduce targeted miRNAs using oligonucleotides that bind their target miRNA and prevent its ligation during library construction, although the extent to which oligonucleotides can be multiplexed and their effect on larger cohorts has not been thoroughly explored. We present a method for suppressing detection of three highly abundant heme miRs in a single multiplexed blocking oligonucleotide reaction. In a small paired-sample pilot (n = 8) and a large cohort of samples (n = 901), multiplexed oligos reduced detection of their target miRNAs by approximately 70%, allowing for an approximately 10-fold increase in reads mapping to nonheme miRs and increased detection of very lowly expressed miRs, with minimal off-target effects. By removing all three highly expressed erythropoietic miRNAs from next-generational sequencing libraries, this commercially available multiplexed blocking oligonucleotide method allows for greater detection of lowly expressed biomarkers, improving the efficacy, cost-efficiency, and sensitivity of biomarker studies and diagnostic tests.

Indexed as

AdultCohort StudiesHemolysisHumansMicroRNAsOligonucleotidesRNAMicroRNAsOligonucleotidesRNA

Identifiers

PMID33872788
PMCPMC8207476
OpenAlexW3152716657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.